Bluejay Diagnostics (BJDX) Capital Expenditures (2021 - 2026)

Bluejay Diagnostics has disclosed Capital Expenditures across 5 years of filings, most recently posting $18989.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $18989.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $290339.0 (changed N/A YoY), and the FY2025 annual result was $173735.0, down 43.37% from the prior year.
• Capital Expenditures came in at $18989.0 for Q1 2026 at Bluejay Diagnostics, up from $1125.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $791464.0 in Q3 2022 to a low of $227.0 in Q3 2024.
• The 4-year median for Capital Expenditures is $87894.0 (2023), against an average of $171477.5.
• Across the five-year window, Capital Expenditures soared 18392.15% in 2022 and plunged 99.7% in 2024, its largest moves.
• Bluejay Diagnostics' Capital Expenditures stood at $238207.0 in 2022, then plunged by 63.1% to $87894.0 in 2023, then plunged by 98.72% to $1125.0 in 2024, then jumped by 1587.91% to $18989.0 in 2026.
• The last three Capital Expenditures figures came in at $18989.0 (Q1 2026), $1125.0 (Q4 2024), and $227.0 (Q3 2024), per Business Quant data.